Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Research & Development for 3 consecutive years, with $19.7 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Research & Development rose 10.75% year-over-year to $19.7 million, compared with a TTM value of $96.8 million through Dec 2021, up 100.85%, and an annual FY2024 reading of $51.3 million, down 13.54% over the prior year.
  • Research & Development was $19.7 million for Q4 2021 at Black Diamond Therapeutics, down from $27.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $27.6 million in Q3 2021 and bottomed at $3.0 million in Q1 2019.
  • Average Research & Development over 3 years is $15.4 million, with a median of $15.3 million recorded in 2020.
  • Peak annual rise in Research & Development hit 210.31% in 2021, while the deepest fall reached 10.75% in 2021.
  • Year by year, Research & Development stood at $5.6 million in 2019, then surged by 215.16% to $17.8 million in 2020, then rose by 10.75% to $19.7 million in 2021.
  • Business Quant data shows Research & Development for BDTX at $19.7 million in Q4 2021, $27.6 million in Q3 2021, and $26.7 million in Q2 2021.